Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 4Sarcoma 4Genitourinary 4Gastrointestinal 4CNS 4Other solid neoplasm 3Endocrine 3Dermatologic 3Breast 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2NET 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × vatalanib × Breast × Clear all
NCT00268918 2018-07-27

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00216047 2015-12-09

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Hoosier Cancer Research Network

Phase 1/2 Terminated
7 enrolled
Breast

Breast Neoplasms

NCT00263198 2013-05-07

PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

Washington University School of Medicine

Phase 2 Terminated
4 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡